Mood Swings: When to See a Doctor

What Counts as a "Mood Swing" vs. Normal Emotional Variation

Everyone experiences emotional ups and downs. A bad meeting at work, a poor night of sleep, or a looming deadline can shift your mood within hours. These fluctuations are part of healthy emotional regulation and do not require medical attention.

A mood swing becomes clinically relevant when the shift is disproportionate to the trigger, when it persists beyond a reasonable time frame, or when it impairs your ability to function. The DSM-5-TR distinguishes normal sadness from a depressive episode by requiring at least five symptoms present for two or more weeks, including depressed mood or loss of interest. On the other end, the manual defines manic episodes as lasting at least seven days with marked impairment [1]. The two-week and one-week thresholds are not arbitrary. They reflect the point at which mood disturbance statistically predicts functional decline and treatment benefit.

A useful self-check: if you cannot identify a proportionate reason for your mood shift, or if the intensity surprises the people around you, that gap between stimulus and response is worth documenting. Write down the date, the trigger (if any), the mood shift, and how long it lasted. This log becomes one of the most valuable things you can bring to a first appointment.

Common Causes of Mood Swings

Mood instability has a differential diagnosis that spans endocrinology, psychiatry, neurology, and pharmacology. The cause matters because treatment differs dramatically depending on the root.

Thyroid dysfunction is one of the most frequently missed contributors. Hypothyroidism slows neurotransmitter metabolism, producing depressive symptoms, while hyperthyroidism accelerates it, mimicking anxiety or mania. A 2018 meta-analysis published in JAMA Psychiatry found that individuals with subclinical hypothyroidism had a 1.78-fold increased risk of depression compared to euthyroid controls (95% CI 1.11-2.86) [2]. The Endocrine Society's 2014 clinical practice guideline recommends TSH screening in any patient presenting with new-onset mood symptoms [3].

Perimenopause and menopause produce mood changes through declining and fluctuating estradiol levels. The Study of Women's Health Across the Nation (SWAN) followed 3,302 women over seven years and found that women in the menopausal transition were 2 to 4 times more likely to report depressive symptoms than premenopausal women, even after adjusting for prior depression history [4]. The North American Menopause Society (NAMS) position statement identifies the late perimenopausal window as the period of highest psychiatric vulnerability [5].

Low testosterone in men correlates with irritability, depressed mood, and reduced stress tolerance. A cross-sectional analysis of 4,494 men in the European Male Aging Study found that total testosterone below 8 nmol/L was associated with significantly higher scores on the Beck Depression Inventory (P<0.001) [6]. Testosterone replacement in symptomatic hypogonadal men has shown mood improvement in multiple randomized trials, though effect sizes are moderate [7].

Premenstrual dysphoric disorder (PMDD) affects 3-8% of menstruating women, according to ACOG Practice Bulletin No. 228 [8]. PMDD is not "bad PMS." It involves severe irritability, dysphoria, or anxiety that begins in the luteal phase and resolves within days of menstruation, causing marked impairment each cycle.

Bipolar spectrum disorders affect an estimated 4.4% of U.S. adults at some point in their lives, per the National Institute of Mental Health [9]. Bipolar II, which features hypomania rather than full mania, is particularly underdiagnosed because patients seek help during depressive episodes and may not report hypomanic periods as problematic.

Medications that can cause mood instability include systemic corticosteroids (up to 60% of patients on high-dose prednisone report psychiatric effects [10]), hormonal contraceptives, interferons, and certain antiepileptic drugs. The FDA's 2023 safety communication on GLP-1 receptor agonists noted post-marketing reports of suicidal ideation and depression, though a causal link has not been confirmed and a 2024 retrospective cohort study in Nature Medicine found no increased psychiatric risk [11].

Red Flags That Mean You Should Not Wait

Some mood changes require same-day or emergency evaluation. Do not wait two weeks if any of the following are present.

Suicidal ideation or self-harm. Any thought of ending your life, even if it feels passive ("everyone would be better off without me"), qualifies. Call 988 (Suicide and Crisis Lifeline) or go to an emergency department. A 2022 CDC report found that 12.3 million American adults seriously thought about suicide in 2021 [12].

Psychotic features. Hearing voices, seeing things that are not there, or holding fixed beliefs that others recognize as delusional alongside mood changes suggest a psychotic mood episode. This requires urgent psychiatric evaluation.

Rapid onset after starting a new medication. If mood swings begin within days to weeks of starting corticosteroids, hormonal therapy, an antiepileptic, or any new prescription, contact the prescriber before your next scheduled visit.

Mania or hypomania signs. Decreased need for sleep (feeling rested after 2-3 hours), pressured speech, grandiosity, reckless spending, or hypersexuality suggest a manic or hypomanic episode. Dr. Roger McIntyre, Professor of Psychiatry at the University of Toronto, has noted: "The single most reliable early warning sign of a manic episode is a reduced need for sleep that the patient experiences as refreshing rather than distressing" [13].

Danger to others. Intense rage episodes with urges toward violence or actual aggression need immediate assessment.

The Diagnostic Workup: What to Expect at Your Appointment

A thorough evaluation for mood swings combines structured screening, targeted lab work, and a careful medication and substance-use review. You should expect the visit to last 30 to 60 minutes.

Screening questionnaires form the backbone of the psychiatric assessment. The PHQ-9 is the standard depression screener, validated in over 60,000 patients, with a sensitivity of 88% and specificity of 88% at a cutoff score of 10 [14]. The Mood Disorder Questionnaire (MDQ) screens for bipolar spectrum disorders with a sensitivity of 73% and specificity of 90% in psychiatric settings [15]. For PMDD, prospective daily symptom charting over two menstrual cycles is the diagnostic standard per ACOG guidelines [8].

Laboratory tests your provider will likely order:

• TSH and free T4 to rule out thyroid disease
• Total testosterone (men) or estradiol and FSH (women, if perimenopause is suspected)
• Complete blood count (CBC) to screen for anemia, which causes fatigue and mood changes
• Comprehensive metabolic panel (CMP) for electrolyte and glucose abnormalities
• Vitamin D (25-OH) if deficiency is suspected (levels below 20 ng/mL have been associated with increased depressive symptoms [16])
• Cortisol (morning or 24-hour urinary free cortisol) if Cushing syndrome is a concern
• Prolactin if a pituitary adenoma is suspected

The American Association of Clinical Endocrinology (AACE) 2023 updated guidelines recommend this layered approach, starting with TSH and expanding based on clinical findings [17].

Substance and medication review is essential. Alcohol, cannabis, stimulants, and benzodiazepines all affect mood regulation. Your provider will ask about current use, frequency, and timing relative to mood symptoms. Be specific and honest. This information changes the diagnosis.

Treatment Options by Cause

Treatment for mood swings depends entirely on the underlying diagnosis. A blanket prescription for an antidepressant without identifying the cause can worsen bipolar disorder, delay thyroid treatment, or mask a medication side effect.

Thyroid-related mood swings resolve with thyroid hormone optimization. Levothyroxine (Synthroid) is the standard for hypothyroidism, with the American Thyroid Association recommending a starting dose of 1.6 mcg/kg/day in otherwise healthy adults, titrated to a TSH within the reference range [18]. Most patients notice mood improvement within 4-8 weeks of reaching a stable dose.

Perimenopausal mood symptoms respond to hormone therapy in women without contraindications. The 2022 NAMS position statement identifies estradiol-based hormone therapy as effective for mood symptoms during the menopausal transition [5]. For women who cannot or prefer not to use hormones, SSRIs (particularly escitalopram 10-20 mg) and SNRIs (venlafaxine 75-150 mg) are evidence-based alternatives. The NAMS statement notes: "Hormone therapy remains the most effective treatment for vasomotor symptoms and is also effective for mood disturbances in the context of the menopause transition" [5].

PMDD responds to low-dose SSRIs, which can be given continuously or only during the luteal phase (days 15-28 of the cycle). A Cochrane systematic review of 31 randomized trials (N=4,372) found that SSRIs produced a standardized mean difference of -1.72 (95% CI -2.21 to -1.24) on symptom severity compared to placebo [19]. Fluoxetine 20 mg and sertraline 50-100 mg are the most studied options.

Low testosterone in men may warrant testosterone replacement therapy (TRT) when total testosterone is consistently below 300 ng/dL and symptoms are present. The Endocrine Society's 2018 guideline recommends against treating testosterone levels in the normal range for mood symptoms alone [7]. Testosterone cypionate 100-200 mg intramuscularly every 1-2 weeks or topical testosterone 1% gel are standard protocols.

Bipolar disorder requires mood stabilizers, not antidepressants alone. Lithium remains the gold-standard mood stabilizer, with a meta-analysis in The Lancet (Cipriani et al., 2019) confirming its superiority over placebo for preventing both manic and depressive relapse [20]. Valproate, lamotrigine, and second-generation antipsychotics (quetiapine, lurasidone) are alternatives depending on the polarity of episodes.

Medication-induced mood swings typically improve with dose reduction or switching to an alternative agent. For corticosteroid-induced psychiatric effects, tapering to the lowest effective dose is the primary intervention [10].

Lifestyle Interventions That Actually Have Evidence

Several non-pharmacological strategies have randomized-trial support for mood stabilization, and they work best as adjuncts to targeted medical treatment rather than replacements.

Sleep regularity may be the single most modifiable risk factor for mood instability. A 2023 study in NPJ Digital Medicine (N=2,115) found that sleep-timing variability, not just total sleep duration, predicted next-day negative mood with an effect size comparable to that of short sleep duration [21]. Going to bed and waking at the same time daily, including weekends, reduces mood variability.

Aerobic exercise at moderate intensity (150 minutes per week, per CDC physical activity guidelines) has shown antidepressant effects comparable to sertraline in the landmark SMILE trial [22]. The mechanism involves increased BDNF, improved HPA-axis regulation, and enhanced serotonergic tone.

Omega-3 fatty acids (EPA-predominant formulations at 1-2 g/day) showed a modest but significant benefit for depressive symptoms in a meta-analysis of 26 RCTs published in Translational Psychiatry (effect size 0.28, 95% CI 0.10-0.47) [23].

Alcohol reduction deserves direct mention. Alcohol is a CNS depressant that disrupts sleep architecture and depletes serotonin. Even moderate drinking (7-14 drinks per week) has been associated with increased depressive symptom scores in the UK Biobank cohort [24]. If mood swings cluster around drinking days, a 30-day elimination trial is a reasonable diagnostic maneuver.

How to Prepare for Your Doctor Visit

Arriving prepared shortens the path to a diagnosis. Bring three things.

A mood log. Two weeks of daily entries noting your mood on a 1-10 scale, hours of sleep, menstrual cycle day (if applicable), medications taken, alcohol or substance use, and any identifiable triggers. Free apps like Daylio or Bearable work, but a simple spreadsheet is fine.

A complete medication list. Include prescriptions, over-the-counter supplements, hormonal contraceptives, and any recent changes. Note start dates and dose changes.

A timeline of the problem. When did mood swings begin? Was there a life event, medication change, or new symptom around that time? Did anyone in your family have bipolar disorder, depression, or thyroid disease? Family history of bipolar disorder increases your lifetime risk 10-fold, according to a twin study published in Archives of General Psychiatry [25].

Your provider can accomplish more in 30 minutes with these three items than in 60 minutes without them.

Mood Swings in Specific Populations

Postpartum women face unique risk. The "baby blues" (mild mood lability in the first two weeks after delivery) affect up to 80% of new mothers and resolve spontaneously. Postpartum depression, affecting approximately 1 in 8 women per the CDC, persists beyond two weeks and requires treatment [26]. Brexanolone (Zulresso) and the oral neuroactive steroid zuranolone (Zurzuvae) are FDA-approved specifically for postpartum depression, with zuranolone showing response rates of 57% vs. 38% for placebo at Day 45 in the SKYLARK trial [27].

Adolescents and young adults are in a period of neurodevelopmental change that makes mood variability normal to a degree. The warning signs that differentiate pathology from development include functional impairment at school, social withdrawal lasting more than two weeks, and substance use as a coping mechanism. The USPSTF recommends screening for depression in all adolescents aged 12 and older [28].

Older adults may present mood changes as a first sign of neurocognitive decline. Irritability and personality change in a person over 65 should prompt a cognitive screening (Montreal Cognitive Assessment or Mini-Mental State Exam) alongside the mood evaluation.

Patients on GLP-1 receptor agonists for weight management should report new mood symptoms promptly, as the FDA continues post-marketing surveillance for neuropsychiatric effects of semaglutide and tirzepatide [11].